, classic and endemic KS do not occur (Wabinga et al, 1993; Ziegler, 1993; Bhoopat et al, 1994; Sukpanichant et al, 1998) , and the incidence of AIDS-associated KS appears very low (Bhoopat et al, 1994; Sukpanichant et al, 1998) . We investigated the prevalence in healthy individuals of HHV-8 (Table 1) in Southeast Asia (n = 234 from Malaysia and Thailand), Indian subcontinent (n = 188 from India and Sri Lanka), the West Indies (n = 410 from Jamaica and Trinidad), and three African countries (n = 164 from Uganda, Zambia and Ghana) and compared this with healthy donors' sera from the USA (n = 135). Where available, we also tested a limited number of sera from HIV-1-infected patients (Table 2) for HHV-8 antibody to see if the prevalence differed from the healthy population: India (n = 42), Thailand (n = 196), Zambia (n = 25), Uganda (n = 35), Trinidad (n = 12) and the USA (n = 124).
MATERIALS AND METHODS
We employed a recently described whole virus enzyme-linked immunosorbent assay (ELISA; Advanced Biotechnologies Inc, Columbia, MD, USA) using sucrose-banded HHV-8 virus lysate as the source of antigen (Chatlynne et al, 1998) . A whole virus ELISA has advantages over using individual viral proteins as a source of antigen, since the viral lysate contains a broad spectrum of seroreactivity compared to that detected by a single viral protein in ELISA, IFA, or immunoblots. Since this ELISA detects predominantly proteins to lytic antigens, we also compared this ELISA to a lytic antigen IFA in a subset of KS-and HIV-positive patient sera (n = 58). For the ELISA, sera were diluted at least 1:80 and for lytic IFA, sera were tested at a dilution of 1:40. Frozen and coded sera were shipped to the laboratory in Columbia, Maryland, for testing. Serum (obtained from Malaysia, Hong Kong and Sri Lanka) from patients with nasopharyngeal carcinoma, oral carcinoma and other diseases (infectious mononucleosis and African Burkitt's lymphoma) were also titred for Epstein-Barr virus (EBV) to see if patients with high EBV titres also tested positive for HHV-8, and to see if antibodies to EBV might cross-react with HHV-8 (Table 3) . 
Collection of serological samples

Samples from India
These were collected from individuals at blood bank facilities in Bombay, Madras and New Delhi for HIV testing. Therefore, the samples consisted of both healthy donors (HIV-negative) and HIVpositive individuals who were antibody-positive by radioimmunoassay and Western blot.
Samples from nasopharyngeal carcinoma, oral carcinoma, infectious mononucleosis, African Burkitt's lymphoma and from healthy donors and HIV+ patients from Africa Most of the nasopharyngeal carcinoma (NPC) and all of the oral carcinoma (OC) sera were provided by the University of Malaya, Kuala Lumpur. All of the OC sera originally came from Sri Lanka to the University of Malaya for HHV-6/HHV-7 and other studies. The other NPC, African Burkitt's lymphoma (BL), and infectious mononucleosis (IM) sera were obtained from the Department of Microbiology/Immunology, Georgetown University School of Medicine, Washington, DC. These NPC sera originally came from Hong Kong (kindly supplied by Dr Ng). The BL sera (Table 3) from Ghana were originally part of another study on EBV conducted by Drs Robert Bigger and Paul Levine (National Cancer Institute's (NCI) Burkitt's lymphoma project). These sera were collected in the late 1960s and stored at the NCI Natural Products Repository. Some of the African sera (Uganda and Zambia) were made available by the Georgetown University, Washington, DC, the Cancer Research Institute, London, UK and the Natural Products Repository, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland. All of the healthy donors' sera from Ghana were also obtained from the Natural Products Repository of NCI and were collected in 1990 and 1991 from the Roforidua region for other NCI studies (ID = Ghana/Africa, ID = ward controls and ID = Kocle hospital).
Serum samples from Malaysia
These were collected from healthy donors by two of the authors, Drs Yadav and Norhanom, at the Institute of Advanced Studies, University of Malaya, as a part of an EBV seroepidemiology study. These sera were obtained from Chinese, Malays and Indians, whereas the NPC sera were from Chinese and Malays. These sera were stored at the University facility at -20°C.
Serum samples from Thailand
Serum samples of HIV-negative donors were collected at the Mahidol University of Thailand. The serum samples from HIVpositive donors were collected from the Remune Trail Center. Among the healthy donors (HIV-negative), three were found to be HHV-8 antibody-positive workers who applied for a permit to seek work in the Middle East. The age and sex of four serum samples were not traceable (Table 1) .
Serum samples from Jamaica Sera samples from normal blood donors were obtained from the National Transfusion Service, Kingston, Jamaica.
Serum samples from Trinidad
All samples from Trinidad were collected (Drs Cleghorn, Jack and Edwards) after informed consent from adult STD clinic attendees as part of a larger NIH-funded study to screen for early HIV-1 infection in the period 1995-1997.
Age and sex of donors
Age and sex of individuals from whom sera were collected varied in each group, whether collected at a clinic (as previously indicated), blood bank, or as part of a study group from healthy adults in the USA, India, Sri Lanka, Malaysia, Thailand, Uganda, Zambia, Ghana, Jamaica and Trinidad, and HIV-infected individuals from the USA, India, Trinidad, Thailand, Uganda, Zambia and Ghana (with and without KS). The age (range) and sex distribution of all sera tested are provided in Table 1 , 2 and 3. Table 1 shows the distribution of HHV-8 IgG antibodies in healthy individuals from the countries tested. We used sera from patients with KS for a positive control, and all of these sera were positive for HHV-8 IgG antibody. The prevalence of HHV-8 in 5.2% of blood donors in the USA correlates with that previously reported using both latent IFA and immunoblot assays (Gao et al, 1996a; Kedes et al, 1996; Miller et al, 1996) . The higher prevalence of HHV-8 in adults from Uganda (38.7%) and Zambia (37.5%) correlates with the incidence of endemic KS and the high incidence of AIDS-associated KS in these countries (Wabinga et al, 1993) . In Ghana, however, the high seroprevalence of HHV-8 (41.9%) does not correlate with an increased incidence of African endemic KS (Ziegler, 1993) , indicating that co-factors are probably necessary to precipitate endemic KS (Ziegler, 1993; Bourboulia et al, 1998) . The high seroprevalence of HHV-8 antibody to lytic viral antigens further supports another study of pregnant African women and prostitutes from Cameroon (Bestetti et al, 1998 ) in which 52.6% who were HIV-positive demonstrated IgG antibody to HHV-8, compared to 42.6% who were HIV-negative. This is the first report to document the prevalence of KSHV in the Far East in healthy individuals (Table 1 ) and in HIV-1-positive individuals from these The sera for antibody to EBV-VCA were tested by IFA using P3HR-1 Clone 1B cells of which 20% expressed VCA.
RESULTS AND DISCUSSION
b
The antibody to EBV-EA was tested by IFA on Raji cells superinfected with EBV isolated from P3HR-1 cells. At 48 hours post infection, >50% of the Raji cells expressed EA.
c ND -not done countries ( Table 2) . As in other countries where endemic and classic KS are rare (e.g. Northern America and North Western Europe), HHV-8 infection appears restricted to less than 5% of healthy adults. Similarly, HHV-8 is not a common infection of healthy adults in the two West Indian countries tested: Trinidad (1.3%) and Jamaica (3.6%) (Manns et al, 1998) . In HIV-1-infected populations, seroprevalence of HHV-8 is generally elevated above that of the general population in areas where KS is associated with HIV infection (e.g. USA); but in areas (India, Thailand) where HIV infection is on the increase, the lack of evidence of KS does not correlate. In spite of the high prevalency of HIV and AIDS in India and Thailand, the seroprevalency of HHV-8 is much lower in this population than in comparable HIV-positive populations in the USA or Africa ( Table 2 ). The number of HIV-positive samples from Trinidad is too small to draw any conclusions; however, it may be similar to India and Thailand.
Since infection with EBV is widespread in the Far East and Indian subcontinent and is associated with NPC and endemic Burkitt's lymphoma, we tested sera from 40 patients with NPC from Malaysia and Hong Kong, from 40 patients with oral squamous carcinoma (OC) from Sri Lanka, from seven IM patients in the USA, and from 12 children with BL from Ghana to determine whether there is any immunologic cross-reactivity between the two human gamma herpesviruses, i.e. EBV and HHV-8, using this ELISA (Table 3 ). EBV antibodies were tested by IFA for anti-VCA IgG using a preparation of P3HR-1 cells (Clone 1B) , that is about 20% positive for EBV viral capsid antigen (VCA). IgG and IgA antibody to EBV early antigen (EA) was tested by IFA with Raji cells superinfected with the P3HR-1 strain of EBV. After 48 h superinfection, approximately 60% of the cells are positive for EA as determined by monoclonal antibodies to EA-diffuse (EA-D) and EA-restricted (EA-R) (kindly provided by Dr Gary Pearson of the Georgetown University School of Medicine, Washington, DC). To test for EBV IgM, sera were first preabsorbed to remove IgG antibodies and then incubated on fixed P3HR-1 cells for 3 h. Table 3 shows the results of this study. The 42 NPC patients had very high IgG and IgA antibody titres to EBV-VCA and EBV-EA, but only two of these patients demonstrated antibodies to HHV-8. In addition, one serum from 40 patients with OC tested positive for HHV-8 IgG. Out of 12 BL patients with antibody to EBV, one had antibody to HHV-8. Seven IM sera with EBV IgM antibody were all negative for HHV-8 IgG. The titres of HHV-8 IgG-positive sera, i.e. NPC, OC and BL, are given in Table 3 , which showed that the titres were not elevated (as observed in KS sera) (Chatlynne et al, 1998) in spite of the high EBV titres antibody (Table 3 ). This supports a lack of cross-reactivity between HHV-8 and anti-EBV antibodies in this ELISA, and further indicates that the HHV-8 IgG antibody detected in the general populations, HIVpositive individuals, and KS patients of the various countries tested was specific. This data further supports our previous finding where KS sera, after adsorption for EBV antibody, retained the HHV-8 IgG (Chatlynne et al, 1998) .
In this study, we show that HHV-8 is not a common human pathogen in Southeast Asia or the Caribbean. Current data indicate that HHV-8 infection is more prevalent in countries where classic and endemic KS occurs . In these countries, horizontal transmission and mother-to-child transmission are likely to occur (Bourboulia et al, 1998; Luppi et al, 1998; Gessain et al, 1999) . In countries with a low incidence of classic or endemic KS, HHV-8 is predominantly found in homosexual men at risk of developing KS Martin et al, 1998; Verbeek et al, 1998) , and is a sexually transmitted agent among these individuals (Martin et al, 1998) . In Southeast Asia and the Caribbean, HHV-8 might be a relatively newly introduced pathogen. The restricted distribution of HHV-8 in these populations also correlates with the relatively low incidence of reported cases of classical KS or AIDS KS (Gill, personal communication, 1998; Jensen, personal communication, 1998) . Longitudinal follow-up studies of individuals infected with HHV-8 in Southeast Asia and the Caribbean will help to assess the participation of this viral agent in the pathogenesis of KS and other diseases or malignancies. Future studies will attempt to determine the mode(s) of transmission of HHV-8 in the Far East and whether HHV-8 was present in sera collected prior to the AIDS epidemic.
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